Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
THE UNMET NEED IN O VA R I A N C ANCE R THE PREVALENCE AND CHALLENGES OF OVARIAN CANCER Early symptoms are non-specific and difficult to detect:iv,v Bloating Pelvic/Abdominal pain Difficulty eating Urinary issues Ovarian cancer is the FIFTH MOST DEADLY cancer in womeni,ii 61% of women with ovarian cancer are diagnosed in an advanced stage,v when prognosis is poor ~22,000 new cases will be diagnosed in 2016 in the U.S.iii ~65,000 new cases were diagnosed in Europe in 2012ii Despite the unmet need, there have been few new treatment options introduced for patients with ovarian cancer over the past several decades. I POSI TIVE RE SP ON SE Even though most patients with high-grade serous ovarian cancer respond well to standard therapy... Platinum-Based Chemotherapy TR T NI L IA RE CUR RENCE RA TE For ~85% E AT M E N T of patients, the disease will RECUR vi Up to ~80% of women living with ovarian cancer are afraid of recurrence.vii,viii Most women who recur are treated with chemotherapy and then undergo “watchful waiting” which can lead to anxiety and uncertaintyix,x But each round of chemotherapy leads to diminishing effectiveness and a sobering reality... Cumulative toxicities increasexii Platinum-based chemotherapy becomes less effectivexi Progression-free survival becomes shorterxi Together, as a community, we are working towards fulfilling the unmet needs of women with ovarian cancer, including earlier diagnosis, reducing recurrence rates and extending the time between treatments. LEARN MORE ABOUT TESARO'S COMMITMENT TO OVARIAN CANCER AT TES AR O BI O . C O M i. ii. iii. iv. v. Siegel, R., J. Ma, Z Zou, and A Jemal. 2014. “Cancer Statistics, 2014.” CA: A Cancer Journal for Clinicians 64 (1): 9–29. doi:10.3322/caac.21208. WHO, IARC GLOBOCAN, Cancer Incidence and Mortality Worldwide in 2008 at http://globocan.iarc.fr/. Last Accessed September 28, 2016. National Cancer Institute. 2016. “Cancer of the Ovary - SEER Stat Fact Sheets.” http://seer.cancer.gov/statfacts/html/ovary.html. Last Accessed June 23, 2016. American Cancer Society. 2014. “Signs and Symptoms of Ovarian Cancer.” http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Last Accessed Septmber 28, 2016. American Cancer Society. 2015. Cancer Facts & Figures 2015. Atlanta: American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/. Last Accessed June 23, 2016. vi. Birrer, M., and K. Fujiwara. 2016. “Medical Treatment for Relapsed Epithelial Ovarian, Fallopian Tubal, or Peritoneal Cancer: Platinum-Resistant Disease.” UpToDate. http://www.uptodate.com/contents/medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-resistant-disease. Last Accessed June 23, 2016. vii. Mirabeau-Beale KL, Kornblith AB, Penson RT, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecologic Oncology. 2009;114(2):353-359. viii. Cesario SK, Nelson LS, Broxson A, et al. Sword of Damocles cutting through the life stages of women with ovarian cancer. Oncol Nurs Forum. 2010 Sep; 37(5): 609–617. ix. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer. 2003;98(5):1061-1071. x. Reb AM. Transforming the death sentence: elements of hope in women with advanced ovarian cancer. Oncology Nursing Forum. 2007;34(6):E70-E81. xi. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605-2612. xii. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2006;102(3):432-439. TESARO, Inc. | 1000 Winter Street | Waltham, MA 02451 TESARO Bio GmbH | Poststrasse 6, 6300 | Zug, Switzerland TESARO and the logo design presented in this material are trademarks of TESARO, Inc. ©2016 TESARO, Inc. All rights reserved. US.NR.CC.06160081b